Kate Bingham - 13 Jul 2021 Form 4/A - Amendment Insider Report for BICYCLE THERAPEUTICS plc (BCYC)

Reporting relationship: Director
Issuer ticker: BCYC
Reported as of: 13 Jul 2021
Net transaction value: -$1,526,467
SEC form: 4/A - Amendment
Accepted by SEC: 20 Jul 2021, 16:17:27 UTC
Original report date: 15 Jul 2021
Source filing: View source filing
Reporting owner signature: /s/ Kate Bingham

Key filing fact

Kate Bingham filed Form 4/A - Amendment for BICYCLE THERAPEUTICS plc (BCYC) on 20 Jul 2021.

Key facts

This page summarizes Kate Bingham's Form 4/A - Amendment filing for BICYCLE THERAPEUTICS plc (BCYC).
4 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 20 Jul 2021, 16:17.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: -$1,526,467.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCYC transaction

Ordinary Shares

Sale

Transaction value: $19,698
Shares: -588
Change %: -0.03%
Price: $33.50
Shares after: 1,875,049
Date: 13 Jul 2021
Ownership: By SV Life Sciences Fund V, L.P.
Footnotes: F1, F2

BCYC transaction

Ordinary Shares

Sale

Transaction value: $1,475,182
Shares: -43,378
Change %: -2.3%
Price: $34.01
Shares after: 1,831,671
Date: 14 Jul 2021
Ownership: By SV Life Sciences Fund V, L.P.
Footnotes: F1, F2

BCYC transaction

Ordinary Shares

Sale

Transaction value: $402
Shares: -12
Change %: -0.03%
Price: $33.50
Shares after: 39,625
Date: 13 Jul 2021
Ownership: By SV Life Sciences Fund V Strategic Partners, L.P.
Footnotes: F3, F4

BCYC transaction

Ordinary Shares

Sale

Transaction value: $31,185
Shares: -917
Change %: -2.3%
Price: $34.01
Shares after: 38,708
Date: 14 Jul 2021
Ownership: By SV Life Sciences Fund V Strategic Partners, L.P.
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Kate Bingham is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.

Footnote F2

These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.

Footnote F3

These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.

Footnote F4

These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.

SEC remarks

The original Form 4 filed on July 15, 2021 is amended by this Form 4 amendment to reflect Ms. Bingham's resignation from the Board of Directors effective as of the Annual Meeting held on June 28, 2021. As a result of her resignation, Ms. Bingham is no longer subject to Section 16 reporting requirements.